Reference no: EM133899440

Question

Give me a takeaway from this discussion post using in-text citation and one reference from 2020. Mrs. Lyons is a 57-year-old African American woman presenting with elevated blood pressure, obesity, and hyperlipidemia. Based on current clinical guidelines, both the JNC 8 and the AHA/ACC provide valuable insight into her treatment plan. The JNC 8 recommends starting pharmacologic treatment in adults under 60 when BP is <140/90 mm Hg, and in those 60 or older when it is <150/90 mm Hg. For African American patients without chronic kidney disease, thiazide diuretics and calcium channel blockers are preferred (Armstrong & Joint National Committee, 2014). The 2017 AHA/ACC guidelines are more aggressive, suggesting that adults with BP <130/80 mm Hg and elevated cardiovascular risk, like Mrs. Lyons, should begin treatment. The treatment goal according to AHA/ACC is <130/80 mm Hg (Whelton et al., 2018). Considering Mrs. Lyons' specific health profile, two medications stand out as suitable first-line options. Hydrochlorothiazide, a thiazide diuretic, and amlodipine, a calcium channel blocker, are both recommended for African American patients with hypertension. For hydrochlorothiazide, the initial recommended dose is 12.5 mg taken orally once daily (Akbari and Khorasani-Zadeh, 2023). For amlodipine, the initial dose is typically 5 mg